Journal of Dermatological Treatment (Dec 2024)
Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study – IL PSO (Italian Landscape Psoriasis)
- D. Orsini,
- M. Megna,
- C. Assorgi,
- A. Balato,
- R. Balestri,
- N. Bernardini,
- A. Bettacchi,
- T. Bianchelli,
- L. Bianchi,
- G. Buggiani,
- M. Burlando,
- AMG. Brunasso,
- G. Caldarola,
- N. Cameli,
- A. Campanati,
- E. Campione,
- A. Carugno,
- K. Chersi,
- A. Conti,
- A. Costanzo,
- E. Cozzani,
- A. Cuccia,
- D. D’Amico,
- G. Dal Bello,
- E. G. Dall’Olio,
- P. Dapavo,
- C. De Simone,
- E. V. Di Brizzi,
- A. Di Cesare,
- V. Dini,
- M. Esposito,
- E. Errichetti,
- M. C. Fargnoli,
- C. S. Fiorella,
- A. Foti,
- Z. Fratton,
- F. M. Gaiani,
- P. Gisondi,
- R. Giuffrida,
- A. Giunta,
- C. Guarneri,
- A. Legori,
- F. Loconsole,
- P. Malagoli,
- A. Narcisi,
- M. Paolinelli,
- L. Potestio,
- F. Prignano,
- G. Rech,
- A. Rossi,
- N. Skroza,
- F. Trovato,
- M. Venturini,
- A. G. Richetta,
- G. Pellacani,
- A. Dattola
Affiliations
- D. Orsini
- Clinical Dermatology Unit, San Gallicano Dermatological Institute (IRCCS), Rome, Italy
- M. Megna
- Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
- C. Assorgi
- Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
- A. Balato
- Unit of Dermatology, University of Campania Luigi Vanvitelli, Naples, Italy
- R. Balestri
- Division of Dermatology, Psoriasis Outpatient Service, APSS – Azienda Provinciale per i Servizi Sanitari, Trento, Italy
- N. Bernardini
- Dermatology Unit "Daniele Innocenzi", ASL Latina Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Italy
- A. Bettacchi
- UOC of Dermatology, Hospital of Macerata, ASUR Marche AV3, Macerata, Italy
- T. Bianchelli
- Dermatology Unit, Istituto Nazionale di Riposo e Cura per Anziani, INRCA-IRCCS Hospital, Ancona, Italy
- L. Bianchi
- Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
- G. Buggiani
- S.O.S.D. Dermatologia San Giuseppe, Azienda USL Toscana Centro, Firenze, Italy
- M. Burlando
- Dermatologic Clinic, DISSAL, ospedale Policlinico San Martino-IRCCS, Genova, Italy
- AMG. Brunasso
- Department of Internal Medicine, Villa Scassi Hospital ASL3, Genoa, Italy
- G. Caldarola
- Section of Dermatology, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy
- N. Cameli
- Clinical Dermatology Unit, San Gallicano Dermatological Institute (IRCCS), Rome, Italy
- A. Campanati
- Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
- E. Campione
- Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
- A. Carugno
- Dermatology Unit, Department of Medicine and Surgery, University of Insubria, Varese, Italy
- K. Chersi
- Dermatology Unit, ASUGI Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy
- A. Conti
- Dermatologic Unit, Department of Surgery, Infermi Hospital of Rimini, AUSL Romagna, Rimini, Italy
- A. Costanzo
- Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy
- E. Cozzani
- Dermatologic Clinic, DISSAL, ospedale Policlinico San Martino-IRCCS, Genova, Italy
- A. Cuccia
- Unit of Dermatology, San Donato Hospital, Arezzo, Italy
- D. D’Amico
- UOC Dermatologia, AOU "R. Dulbecco" – Catanzaro, Catanzaro, Italy
- G. Dal Bello
- Dermatology Unit, ASST Mantova, Mantova, Italy
- E. G. Dall’Olio
- Dermatology Unit, ASUGI Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy
- P. Dapavo
- Department of Biomedical Science and Human Oncology, Second Dermatologic Clinic, University of Turin, Turin, Italy
- C. De Simone
- Section of Dermatology, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy
- E. V. Di Brizzi
- Unit of Dermatology, University of Campania Luigi Vanvitelli, Naples, Italy
- A. Di Cesare
- Department of Health Sciences, Dermatology Session, University of Florence, Florence, Italy
- V. Dini
- Dermatology Unit, Department of Clinical and Experimental Medicine, Ospedale Santa Chiara, Pisa, Italy
- M. Esposito
- Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy.;
- E. Errichetti
- Institute of Dermatology, Department of Medicine, University of Udine, Udine, Italy
- M. C. Fargnoli
- Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy.;
- C. S. Fiorella
- Dermatology Unit - Oncology and Ematology Department, PO M.R Dimiccoli, Barletta, Italy
- A. Foti
- Unit of Dermatology and Cosmetology, IRCCS Ospedale San Raffaele, Milan, Italy
- Z. Fratton
- Institute of Dermatology, Department of Medicine, University of Udine, Udine, Italy
- F. M. Gaiani
- Department of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato Milanese, Milan, Italy
- P. Gisondi
- Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy
- R. Giuffrida
- Department of Clinical and Experimental Medicine, Dermatology, University of Messina, Messina, Italy
- A. Giunta
- S.O.S.D. Dermatologia San Giuseppe, Azienda USL Toscana Centro, Firenze, Italy
- C. Guarneri
- Department of Biomedical, Dental Sciences and Morphofunctional Imaging, Section of Dermatology, University of Messina, Messina, Italy
- A. Legori
- UO Dermatologia, IRCCS Ospedale Galeazzi & Università degli Studi di Milano, Milan, Italy
- F. Loconsole
- Department of Dermatology, University of Bari, Bari, Italy
- P. Malagoli
- Department of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato Milanese, Milan, Italy
- A. Narcisi
- Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy
- M. Paolinelli
- Dermatologic Unit, Department of Surgery, Infermi Hospital of Rimini, AUSL Romagna, Rimini, Italy
- L. Potestio
- Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
- F. Prignano
- Department of Health Sciences, Dermatology Session, University of Florence, Florence, Italy
- G. Rech
- Division of Dermatology, Psoriasis Outpatient Service, APSS – Azienda Provinciale per i Servizi Sanitari, Trento, Italy
- A. Rossi
- Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy
- N. Skroza
- Dermatology Unit "Daniele Innocenzi", ASL Latina Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Italy
- F. Trovato
- Dermatology Department, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Italy
- M. Venturini
- Dermatology Department, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Italy
- A. G. Richetta
- Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, Italy
- G. Pellacani
- Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, Italy
- A. Dattola
- Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, Italy
- DOI
- https://doi.org/10.1080/09546634.2024.2393376
- Journal volume & issue
-
Vol. 35,
no. 1
Abstract
Purpose of the article: The aim of this multicenter observational study is to report data from real world on the use of bimekizumab in patients aged ≥ 65 years with moderate-to-severe plaque psoriasis. Elderly patients are poorly represented in clinical trials on bimekizumab for plaque psoriasis, and real-world studies are important to guide clinical choices.Materials and methods: A retrospective multicenter study was conducted in 33 dermatological outpatient clinics in Italy. Patients aged ≥ 65 years, with moderate-to-severe plaque psoriasis and treated with bimekizumab were enrolled. No exclusion criteria were applied. Bimekizumab was administered following the Italian Guidelines for the management of plaque psoriasis and according to the summary of product characteristics, in adult patients who were candidates for systemic treatments. Overall, 98 subjects were included, and received bimekizumab up to week 36. Clinical and demographic data were collected before the initiation of treatment with bimekizumab. At baseline and each dermatological examination (4, 16, and 36 weeks), clinical outcomes were measured by the following parameters: (1) PASI score; (2) site-specific (scalp, palmoplantar, genital, nail) Psoriasis Global Assessment (PGA). At each visit, the occurrence of any adverse events (AEs) was recorded, including serious AEs and AEs leading to bimekizumab discontinuation.Results: The mean PASI score was 16.6 ± 9.4 at baseline and significantly decreased to 4.3 ± 5.2 after 4 weeks (p < 0.001), and 1.1 ± 1.7 after 16 week (p < 0.001). This level of improvement was maintained after 36 weeks (p < 0.001). PASI ≤2 was recorded in 36 (36.7%) at week 4, 68% and 69.4% at week 16 and 36, respectively. By week 16, 86/98 (87.8%) patients reached PASI75, 71/98 (72.4%) obtained PASI90, and 52/98 (53.1%) PASI100. Binary logistic regression tests showed a significant association of PASI100 by week 4 with lower PASI at baseline. PASI 100 at 16 or 36 weeks was not associated with baseline PASI, obesity, age, gender, previously naïve state, and presence of psoriatic arthritis. Patients naïve to biologics at baseline had similar response to bimekizumab as non-naïve subjects.Conclusions: Bimekizumab is a suitable option for elder patients as it is effective, tolerated and has a convenient schedule.
Keywords
